← back to search

Nicholas J. Maragakis

Cedars-Sinai Medical Center · US
Area of research
Neurology · Genetics
Research interest
Research interests include Amyotrophic Lateral Sclerosis Research, Neurogenetic and Muscular Disorders Research, Parkinson's Disease Mechanisms and Treatments, and Neurogenesis and neuroplasticity mechanisms.
h-index
56
citations
11,553
works
184
NIH funding
primary concept
Amyotrophic lateral sclerosis
email

Recent publications

Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment.
2026cited by 1position: contributordoi
Development of a human iPSC-derived corticospinal tract-on-a-chip
Cell Reports Methods 2026cited by 0position: contributordoi
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
JAMA Network Open 2025cited by 15position: middledoi
Longitudinal study of gesture decoding in a clinical trial participant with ALS
2025cited by 0position: contributordoi
Development of a Human iPSC-Derived “Corticospinal Tract-on-a-Chip” for Neurodegenerative Disease Research
2025cited by 0position: contributordoi
Self-paced silent speech brain-computer interface for device control
2025cited by 0position: contributordoi
Disease related changes in ATAC-seq of iPSC-derived motor neuron lines from ALS patients and controls
Nature Communications 2024cited by 12position: middledoi
Exploring P2X7 receptor antagonism as a therapeutic target for neuroprotection in an hiPSC motor neuron model.
2024cited by 4position: contributordoi
Altered development and network connectivity in a human neuronal model of 15q11.2 deletion-related neurodevelopmental disorders
2024cited by 0position: contributordoi
Stable Decoding from a Speech BCI Enables Control for an Individual with ALS without Recalibration for 3 Months.
2023cited by 50position: contributordoi
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.
2023cited by 21position: contributordoi
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2023cited by 14position: middledoi
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
2023cited by 13position: contributordoi
Phase-Amplitude Coupling Detection and Analysis of Human 2-Dimensional Neural Cultures in Multi-well Microelectrode Array in Vitro
2023cited by 0position: contributordoi
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines
Nature Neuroscience 2022cited by 153position: middledoi
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines.
2022cited by 134position: contributordoi
Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data
Nature Computational Science 2022cited by 50position: middledoi
Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS.
2022cited by 48position: contributordoi
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers
JAMA Neurology 2022cited by 36position: middledoi
Publisher Correction: Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS.
2022cited by 0position: contributordoi
Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS
Nature Neuroscience 2021cited by 77position: middledoi
Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS.
2021cited by 61position: contributordoi
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
2021cited by 34position: contributordoi
Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets
Neuroscience Letters 2021cited by 23position: contributordoi
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
New England Journal of Medicine 2020cited by 533position: middledoi
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
JAMA Neurology 2020cited by 136position: middledoi
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Muscle & Nerve 2020cited by 101position: middledoi
Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>‐19 pandemic: Challenges and opportunities
Muscle & Nerve 2020cited by 59position: middledoi
Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery
Experimental Neurology 2020cited by 13position: contributordoi
Answer ALS: A Large-Scale Resource for Sporadic and Familial ALS Combining Clinical Data with Multi-Omics Data from Induced Pluripotent Cell Lines
2020cited by 3position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 18 papers (2020–2026)Jeremy M. Shefner · Mayo Clinic in Florida5 papers (2012–2022)Christopher J. Donnelly · University of Pittsburgh4 papers (2013–2016)Merit Cudkowicz · Harvard University4 papers (2017–2022)Jeffrey D. Rothstein · German Center for Neurodegenerative Diseases4 papers (2013–2022)Namita Goyal · The NorthCap University4 papers (2012–2021)Jonathan D. Glass · Emory University4 papers (2013–2022)Arens Taga · Johns Hopkins University4 papers (2022–2025)James D. Berry · Buffalo State University3 papers (2020–2022)Nathan E. Crone · Johns Hopkins University3 papers (2023–2025)Seward B. Rutkove · Beth Israel Deaconess Medical Center3 papers (2012–2013)Jean‐Philippe Richard · Johns Hopkins Medicine3 papers (2014–2016) · 3 papers (2023–2025)Khalil Rust · Johns Hopkins University3 papers (2022–2025)Griffin W. Milsap · Johns Hopkins University3 papers (2023–2025)Raha Dastyeb · Johns Hopkins University3 papers (2022–2024)Christa W. Habela · Johns Hopkins University3 papers (2023–2025)Christopher Coogan · Johns Hopkins University3 papers (2023–2025)Miguel Angrick · Johns Hopkins University3 papers (2023–2025)Nick F. Ramsey · Radboud University Nijmegen3 papers (2023–2025)